Incyte Corp. stock underperforms Monday when compared to competitors
Incyte Corp. (INCY) stock fell 1.06% on Monday, closing at $115.62, even as the broader market saw gains with the S&P 500 Index rising 0.72% and the Dow Jones Industrial Average increasing by 0.29%. This decline ended a two-day winning streak for Incyte Corp.
Incyte Corporation completed the acquisition of Vega Therapeutics, Inc. from Star OpCo, Inc.
Incyte Corporation has successfully acquired Vega Therapeutics, Inc. from Star OpCo, Inc. for a total consideration of $2 billion. The acquisition, which includes a cash payment of $1.25 billion and up to $750 million in sales milestone payments, adds VGA039, a novel monoclonal antibody, to Incyte's hematology portfolio. This move is expected to be highly accretive to Incyte's growth post-2029.
Incyte Completes Vega Therapeutics Acquisition, Adding Novel mAb to Hematology Portfolio
Incyte has finalized its $1.25 billion acquisition of Vega Therapeutics, a subsidiary of Star Therapeutics, adding the novel monoclonal antibody VGA039 to its hematology portfolio. VGA039 is currently in Phase III development for von Willebrand disease (VWD), a common inherited bleeding disorder, and is intended to be a first-in-class, once-monthly subcutaneous prophylactic therapy. The acquisition also includes potential additional payments of up to $750 million to Star Therapeutics for sales milestones.
Incyte (INCY) Completes Acquisition of Vega Therapeutics
Incyte (INCY) has successfully acquired Vega Therapeutics, a subsidiary of Star Therapeutics, for $1.25 billion, aiming to bolster its hematology portfolio. This acquisition includes VGA039, a monoclonal antibody for von Willebrand disease in Phase 3 development, which could offer a significant advancement in treatment. Despite a strong GF Score™ of 87/100 and an attractive P/E ratio, recent insider selling of $3.7 million warrants investor attention.
Incyte completes $1.25B Vega Therapeutics acquisition
Incyte has completed its acquisition of Vega Therapeutics for $1.25 billion upfront, a deal representing roughly 5% of Incyte’s market capitalization. The acquisition adds VGA039, a monoclonal antibody for von Willebrand disease, to Incyte's hematology portfolio. This monoclonal antibody is currently in Phase 3 development and has received multiple FDA designations.
Incyte completes $1.25B acquisition of Vega Therapeutics
Incyte has completed its acquisition of Vega Therapeutics for an upfront payment of $1.25 billion, adding VGA039, a monoclonal antibody for von Willebrand disease, to its hematology pipeline. The deal also includes up to $750 million in potential milestone payments to Star Therapeutics. This acquisition is expected to be recorded as a one-time R&D expense in Incyte's Q3 and full-year 2026 financial results.
Incyte pays $1.25B for Vega, adding a Phase 3 bleeding-disorder drug
Incyte has completed its acquisition of Vega Therapeutics for $1.25 billion upfront, with potential additional payments of up to $750 million based on sales milestones. This acquisition strengthens Incyte's hematology portfolio by adding VGA039, a novel Phase 3 investigational monoclonal antibody designed to treat von Willebrand disease, the most common inherited bleeding disorder. VGA039 has received multiple regulatory designations, including Breakthrough Therapy, and aims to be the first once-monthly subcutaneous prophylactic therapy for VWD.
ADAG - Adagene Inc ADR Website Traffic and Mobile Apps Usage
This article provides comprehensive financial data, performance metrics, and news headlines for Adagene Inc. (ADAG). It includes details like market capitalization, P/E ratios, EPS, sales figures, institutional and insider ownership, and recent analyst ratings and company announcements. The data covers a range of financial and operational aspects, offering a snapshot of Adagene's market position and recent activities.
ALKS - Alkermes plc Volatility & Greeks
This article provides a detailed financial overview of Alkermes plc (ALKS), including its stock performance, key financial ratios, and volatility metrics. It lists various financial data points like market capitalization, sales, income, P/E ratio, and recent stock performance over different periods. The data covers profitability, efficiency ratios, and insider/institutional ownership, alongside volatility and Greek parameters relevant to options trading.
IVVD - Invivyd Inc Short Interest
This article provides a detailed financial overview and short interest data for Invivyd Inc (IVVD). It includes key metrics such as market capitalization, sales, earnings per share, and various performance indicators. The data highlights the company's short interest, institutional ownership, and recent stock performance trends.
ANRO - Alto Neuroscience Inc Revenue Breakdown
This article provides a detailed financial overview of Alto Neuroscience Inc (ANRO), including its market capitalization, income, sales, and various financial ratios. It also highlights performance metrics such as stock volatility, analyst recommendations, and insider/institutional ownership. The company, which is in the healthcare biotechnology sector, shows significant year-to-date and yearly performance gains.
The Jakafi from Incyte - a long-running myelofibrosis therapy anchor
Jakafi, marketed by Incyte, has been a cornerstone oral therapy for myelofibrosis in the US for over a decade, treating intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute GVHD. Despite increasing competition from newer JAK inhibitors, Jakafi maintains a significant market share, supported by extensive clinical experience and long-term safety data. Its commercial success has been crucial to Incyte's financial performance, though patient access in the US remains complex due to high list prices and varying insurance coverage.
Enterprise value to revenue forward of Incyte Corporation – NASDAQ:INCY
This article displays the enterprise value to revenue forward for Incyte Corporation (NASDAQ: INCY). It appears to be a financial snapshot from TradingView, indicating the financial metric for the company. The content primarily shows navigation elements and disclaimers for data provided.
PCVX - Vaxcyte Inc Volatility & Greeks
This article provides a detailed financial overview of Vaxcyte Inc (PCVX), including its stock performance, volatility metrics, and various financial ratios up to July 2nd. It highlights key data such as market capitalization, income, sales, EPS, insider and institutional ownership, and price performance over different periods. The data indicates Vaxcyte's current financial health and market position within the biotechnology sector.
KYMR - Kymera Therapeutics Inc Options
This article provides a detailed financial overview of Kymera Therapeutics Inc (KYMR), including its last closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, sales growth, insider/institutional ownership, and price performance over different periods. The data covers information up to July 02, 2026.
ANRO - Alto Neuroscience Inc Options
This page provides a comprehensive overview of Alto Neuroscience Inc. (ANRO) stock options and key financial data. It includes current stock price, market capitalization, income, sales figures, and various financial ratios, alongside performance metrics, analyst recommendations, and insider/institutional ownership percentages.
Incyte outlines its biotech growth path as investors weigh long-term prospects
Incyte is a biotechnology company focused on developing and commercializing medicines for oncology and immunology, with its business model centered on innovation in small molecules and biologic therapies. The company balances revenue from marketed products with a robust research pipeline, using partnerships to share costs and expand commercial reach. Incyte's stock allows investors exposure to a biotech firm with both current cash generation and long-term development potential, focusing on targeted therapies for unmet medical needs.
GRFS - Grifols SA ADR Short Interest
This article provides a detailed overview of Grifols SA ADR (GRFS) stock, focusing on its short interest and various financial metrics. It includes data on market capitalization, income, sales, dividends, P/E ratio, EPS growth, insider and institutional ownership, profitability margins, and price performance over different periods. The stock closed at $7.16, showing a slight increase, with a short float of 2.33% and a short interest of 6.01 million shares.
GHRS - GH Research PLC Options
This article provides a comprehensive financial overview of GH Research PLC (GHRS), detailing its stock performance, key financial metrics, and insider/institutional ownership. It highlights the company's recent closing price, market capitalization, earnings per share, and various performance indicators over different periods.
If You Invested $1,000 in Incyte Corp (INCY)
This article analyzes the historical performance of Incyte Corp (INCY) stock, demonstrating how a $1,000 investment would have grown over various periods (1, 5, and 10 years). It details INCY's annual returns, highlighting its underperformance compared to the S&P 500 over the last decade, and provides a comprehensive overview of Incyte's biopharmaceutical operations, therapeutic areas, key products, and pipeline.
APGE - Apogee Therapeutics Inc Revenue Breakdown
This article provides a detailed financial breakdown for Apogee Therapeutics Inc (APGE), including its stock performance, market capitalization, key financial ratios, and institutional ownership. It highlights that the company currently has no sales and is operating at a net loss, while also showing significant stock performance gains over various periods.
GRFS - Grifols SA ADR Latest SEC Filings
This article provides comprehensive financial data and performance metrics for Grifols SA ADR (GRFS). It covers key financial figures like market cap, income, sales, and various ratios, along with stock performance metrics, insider ownership, analyst recommendations, and recent SEC filing information.
Analysts Offer Insights on Healthcare Companies: Incyte (INCY) and Teladoc (TDOC)
Truist Financial analysts have maintained "Hold" ratings on both Incyte (INCY) and Teladoc (TDOC). For Incyte, analyst Srikripa Devarakonda cited a Moderate Buy consensus with a slight downside from its average price target, while Jailendra Singh maintained a Hold rating for Teladoc, also noting a projected downside from its average price target. These ratings suggest analysts are neither significantly bullish nor bearish on the short-term prospects of these healthcare stocks.
PVLA - Palvella Therapeutics Inc Volatility & Greeks
This article provides a detailed financial overview for Palvella Therapeutics Inc (PVLA), including its last close price, market capitalization, income, sales, and various financial ratios. It also covers performance metrics such as volatility, short interest, analyst recommendations, and historical price performance across different periods. The data presented aims to offer a comprehensive snapshot of the company's financial health and market activity.
PHVS - Pharvaris NV Options
This article provides an overview of Pharvaris NV (PHVS) stock options and key financial data. It details market capitalization, enterprise value, income, sales, per-share metrics, profitability ratios, and various performance indicators. The data includes analyst recommendations, target prices, and insider/institutional ownership figures.
LCTX - Lineage Cell Therapeutics Inc Stock Price and Quote
This article provides a detailed overview of Lineage Cell Therapeutics Inc (LCTX) stock, including its latest stock price, financial metrics, performance indicators, and recent news and analyst ratings. It also details the company's operations as a clinical-stage biotechnology firm focused on cell therapies for various degenerative diseases and cancer, along with insider trading activity.
SLS - SELLAS Life Sciences Group Inc Options
This page provides a detailed financial overview of SELLAS Life Sciences Group Inc (SLS), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS, sales growth, insider/institutional ownership, profitability, and stock performance metrics over different periods. The data indicates recent strong performance with significant percentage increases over weeks, months, and quarters.
LYEL - Lyell Immunopharma Inc Volatility & Greeks
This article provides a detailed financial overview of Lyell Immunopharma Inc (LYEL), including its stock performance, key financial metrics, volatility indicators, and ownership data. It presents a snapshot of the company's market capitalization, income, sales, earnings per share, and various ratios. The report also highlights insider and institutional ownership, short interest, and analyst recommendations for the biotechnology firm.
Incyte Corp. stock underperforms Thursday when compared to competitors despite daily gains
Incyte Corp. (INCY) stock saw a 2.68% increase on Thursday, ending the day at $116.86. Despite these daily gains and being its second consecutive day of increases, the stock underperformed when compared to broader market indices like the S&P 500 which remained mostly unchanged, and the Dow Jones Industrial Average which rose by 1.14%.
LEGN - Legend Biotech Corp ADR Options
This page provides a detailed financial overview of Legend Biotech Corp (LEGN), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. As of July 2nd, the stock closed at $29.91, showing a slight increase. The data presented covers market capitalization, earnings per share, sales growth, profitability ratios, and options-related information, offering a comprehensive snapshot for potential investors.
GRFS - Grifols SA ADR Forecast, Target Price
This article provides a detailed financial overview and forecast for Grifols SA ADR (GRFS), including key financial metrics, performance indicators, and analyst target prices. It highlights the company's current stock price, dividend information, various valuation ratios, and performance over different timeframes. The data suggests a target price of $14.43 against a last close of $7.16, indicating potential upside according to the provided metrics.
VIR - Vir Biotechnology Inc Latest SEC Filings
This page provides an overview of Vir Biotechnology Inc (VIR) focusing on its latest SEC filings and comprehensive financial data. It includes key stock performance metrics, valuation ratios, and insider/institutional ownership percentages, alongside recent earnings figures and analyst recommendations.
Intuit Stock Is Down, But Is This Dip Different?
Intuit (INTU) is experiencing a stock pullback due to mixed performance, with strong growth in assisted tax and mid-market segments but struggles in the core DIY tax sector. Historically, similar dips have not led to quick recoveries, with a median negative return over the next twelve months. However, the company's underlying business remains sound with healthy revenue growth and cash flow, suggesting this dip might be an opportunity for discerning investors if Intuit can successfully adapt its DIY tax model.
Incyte (INCY): Truist Raises the Price Target to $105 as a Government Settlement Adds $246 Million to Net Sales
Truist Securities analyst Srikripa Devarakonda increased Incyte Corporation's (INCY) price target from $103 to $105 while maintaining a Hold rating. This adjustment follows a $246 million non-cash settlement from a dispute with CMS regarding Incyte's drug Opzelura, which will boost Q2 2026 net sales. Truist also revised its model for Opzelura's gross-to-net ratio and projects Insyte's experimental drug VGA039 to reach $1 billion in peak worldwide sales by 2036.
Incyte (INCY): Truist Raises the Price Target to $105 as a Government Settlement Adds $246 Million to Net Sales
Truist Securities analyst Srikripa Devarakonda increased the price target for Incyte Corporation (INCY) to $105, maintaining a Hold rating. This adjustment was prompted by Incyte's successful dispute with the CMS, adding $246 million to Opzelura's Q2 2026 net sales, and an improved gross-to-net ratio for the drug. Truist also projects Incyte's experimental drug VGA039 for von Willebrand disease to achieve approximately $1 billion in peak worldwide sales by 2036.
CRMD,PEP Revenue Breakdown
This article provides detailed
FULC - Fulcrum Therapeutics Inc Latest SEC Filings
This article provides the latest SEC filings information for Fulcrum Therapeutics Inc. It includes comprehensive financial data, performance metrics, and key statistics for the company as of July 1, 2026. The report details market capitalization, income, sales, share information, and various financial ratios, alongside insider and institutional ownership data.
KYTX - Kyverna Therapeutics Inc Dividends
This article provides comprehensive financial data for Kyverna Therapeutics Inc (KYTX), including its current stock price, market capitalization, income, sales, and various financial ratios. It highlights key performance metrics, insider and institutional ownership, and analyst recommendations, noting that the company does not currently pay dividends.
EVMN - Evommune Inc Options
This article provides a detailed financial overview of Evommune Inc. (EVMN), including its stock performance, market capitalization, key financial ratios, insider and institutional ownership, and analyst recommendations. The company's stock closed at $13.29, experiencing a significant single-day drop of 11.69%, and its options trading status is indicated.
INCB057643 in Combination with Ruxolitinib Improves Symptoms in Patients With Myelofibrosis
A phase 1 LIMBER trial investigated INCB057643, a BET inhibitor, both as monotherapy and in combination with ruxolitinib for treating relapsed/refractory myelofibrosis and other myeloid neoplasms. The study demonstrated promising improvements in anemia, spleen size, and symptom burden, particularly with the combination therapy. While common adverse events included thrombocytopenia and anemia, the initial findings suggest the potential of INCB057643 combinations to improve clinical outcomes for patients.
Incyte Corp. stock underperforms Tuesday when compared to competitors
Incyte Corp. (INCY) stock fell 1.13% on Tuesday, closing at $113.36, despite a general upturn in the market where the S&P 500 and Dow Jones Industrial Average both saw gains. This decline broke a two-day winning streak for the company's shares.
Ascendis drug data show leg alignment kept improving through 2 years
Ascendis Pharma reported positive Week 104 data from its pivotal ApproaCH trial for TransCon CNP in children with achondroplasia. The data showed continued improvements in lower extremity alignment, specifically tibial-femoral angle (TFA) and TFA Z-scores, over two years, with greater improvements in children with pre-existing genu varum. The treatment was generally well-tolerated, reinforcing its potential as a pharmacological treatment for achondroplasia.
AVTX - Avalo Therapeutics Inc Latest SEC Filings
This article provides key financial data and performance metrics for Avalo Therapeutics Inc. (AVTX). It includes details on market capitalization, income, sales, EPS, insider ownership, institutional ownership, and various profitability ratios, alongside recent stock performance and analyst recommendations, all derived from the latest SEC filings.
Incyte Corp gains 16% in a week, boosted by strong Q1 2026 results and new product expansion.
Incyte Corporation's stock surged by 16% in one week due to strong Q1 2026 financial results, including 21% revenue growth and a 56% adjusted EPS increase. The company's performance was also boosted by a favorable European opinion for Opzelura and the strategic acquisition of Vega Therapeutics, reducing its dependence on its main drug, Jakafi. While execution risks remain, analysts are optimistic about Incyte's valuation and pipeline if new products deliver.
Evommune Still Has Shot At Atopic Dermatitis With EVO756 After Urticaria Failure
Evommune's drug EVO756 did not meet its primary endpoint in a Phase IIb trial for chronic spontaneous urticaria (CSU), but the company believes it still has potential for treating atopic dermatitis. This development comes after the trial results, indicating a shift in focus for the drug's therapeutic application.
INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura
Incyte (INCY) shares reached a 52-week high after the company announced a settlement with CMS regarding Opzelura's Medicaid rebate rules, expecting a significant non-cash benefit. Additionally, Opzelura received a positive CHMP opinion for moderate atopic dermatitis in adults, potentially becoming the first steroid-free topical JAK inhibitor in the EU for this condition. The company is also strengthening its pipeline through the acquisition of Vega Therapeutics and has seen progress with its lead drug Jakafi and other therapies.
Incyte (INCY) Surges 5.8%: Is This an Indication of Further Gains?
Incyte (INCY) shares rose 5.8% after the European Medicines Agency's Committee for Medicinal Products for Human Use gave a positive opinion for Opzelura (ruxolitinib) cream to treat moderate atopic dermatitis. The drug, if approved, would be the first steroid-free topical JAK inhibitor for this condition in the EU. Despite this positive development, a recent downward revision in Incyte's earnings per share estimate suggests potential volatility, advising investors to watch the stock closely for sustained strength.
H.C. Wainwright reiterates Incyte stock rating on EU label expansion
H.C. Wainwright has reiterated a Buy rating and $140.00 price target for Incyte (NASDAQ: INCY) following a positive European regulatory opinion for Opzelura. This opinion would expand Opzelura's EU label for moderate atopic dermatitis in adults, moving beyond its current authorization for non-segmental vitiligo. The firm anticipates significant growth opportunities for Incyte in Europe, supported by Opzelura's strong performance and recent positive developments.
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
Mirum Pharmaceuticals (MIRM) saw a 5.5% share price jump, potentially driven by positive Phase II data for zilurgisertib in FOP and its subsequent FDA priority review. Despite this recent strength, the company faces a projected quarterly loss and a 9.5% downward revision in consensus EPS estimates, prompting a "Hold" rating from Zacks. Investors are advised to monitor MIRM closely for future performance amidst these conflicting indicators.
Incyte Corporation(NasdaqGS: INCY) dropped from Russell 1000 Growth Benchmark
Incyte Corporation (NasdaqGS: INCY) has been removed from the Russell 1000 Growth Benchmark, as well as the Russell 3000E Growth Benchmark and the Russell 1000 Growth-Defensive Index, on June 28, 2026. This news follows several analyst adjustments to Incyte's price target and a positive opinion from a European Medicines Agency panel regarding label expansion for Incyte's Opzelura. The company specializes in therapeutic products for cancers and inflammatory disorders.
